NCT06364124View on ClinicalTrials.gov

Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

NARecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2025

Conditions
STEMI
Interventions
DRUG

evolocumab

Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day

PROCEDURE

standard post-treatment for STEMI

standard post-treatment for STEMI

Trial Locations (1)

Unknown

RECRUITING

Beijing luhe hospital, Beijing

All Listed Sponsors
lead

Beijing Luhe Hospital

OTHER